A multicenter randomized study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interferon-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis The Hep-Net International Delta Hepatitis Interventional Trial II

OPtimization of treatment for patients with chronic hepatitis C infected with HCVgenotype 2 or 3: 12 vs. 24 weeks of Treatment EXtension for patients without rapid virological response (OPTEX 2/3)

CENTAUR: Cenicriviroc Efficacy and Safety Study in Adult Subjects with Nonalcoholic Steatohepatitis (NASH)